Nkarta Inc Dossier - Source-backed chat

Nkarta Inc

NKTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.95

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.56Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $183.4M

Enterprise Value $158.4M

Shares Outstanding 74.4M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nkarta, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company's strategic pivot from oncology to autoimmune indications, specifically targeting multiple autoimmune diseases with its lead candidate NKX019, has significantly enhanced its market positioning. Backed by a robust cash runway extending into 2029 and recent regulatory agreements supporting outpatient dosing in community-based settings, Nkarta is well-positioned to deliver high-impact clinical data in 2026. The off-the-shelf nature of its platform offers scalable, standardized treatments that bypass the logistical and safety limitations of autologous CAR-T therapies.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$11.33

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential clinical setbacks, such as safety concerns or insufficient durability of B-cell depletion in the 12 billion cell dose cohort. Slower-than-expected enrollment or regulatory hurdles in outpatient settings could delay milestones, forcing the company to seek dilutive capital earlier than projected.

Base CaseCentral scenario

The base case assumes successful clinical execution of the Ntrust-1 and Ntrust-2 trials, with initial clinical data in late 2026 demonstrating robust safety and complete B-cell depletion. Outpatient dosing expansion successfully drives patient enrollment, and the cash runway remains sufficient to fund operations into 2029 without immediate dilutive financing.

Bull CaseUpside scenario

Nkarta's bull case centers on its proprietary allogeneic, off-the-shelf natural killer (NK) cell therapy platform, led by its CAR-NK candidate NKX019. The primary catalyst is its strategic pivot into autoimmune diseases (such as lupus nephritis, systemic sclerosis, and myositis) through the Ntrust-1 and Ntrust-2 clinical trials. The bull case is heavily supported by the FDA's agreement to protocol amendments allowing outpatient dosing of NKX019, which significantly de-risks clinical execution, reduces patient burden, and expands access to community rheumatology centers. Furthermore, the company maintains a robust cash runway extending into 2029, providing ample funding to reach key clinical data readouts without immediate dilution risk.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Robust cash runway extending into 2029 with $266.7 million in cash and investments as of Q1 2026, providing financial stability.
Strategic pivot to high-growth autoimmune indications with lead candidate NKX019, addressing large underserved markets.
FDA agreement on outpatient dosing and protocol amendments, expanding access to community-based rheumatology centers and reducing patient burden.
Proprietary CAR-NK platform featuring co-expression of membrane-bound IL-15 to enhance cell survival and potency without exogenous cytokines.

Key Investment Risks

Clinical development risk inherent to early-stage (Phase 1) trials, with outcomes highly dependent on upcoming 2026 data readouts.
High historical cash burn rate typical of pre-revenue biotechnology companies.
Intense competition from both established autologous CAR-T therapies and emerging allogeneic cell therapy platforms.
Potential for future equity dilution if clinical timelines extend or operational costs escalate.

Thesis Invalidation Triggers

Failure of NKX019 to demonstrate complete or durable B-cell depletion in upcoming clinical readouts.
Severe adverse safety events (e.g., high-grade cytokine release syndrome or neurotoxicity) that compromise the outpatient safety profile.
Inability to successfully enroll patients in the expanded community-based outpatient cohorts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.